Cargando…
Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
BACKGROUND: The benefit of low‐density lipoprotein cholesterol (LDL‐C) levels in chronic kidney disease populations remains unclear. This study evaluated the cardiovascular and renal outcomes in patients with stage 3 chronic kidney disease with different LDL‐C levels during statin treatment. METHODS...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673722/ https://www.ncbi.nlm.nih.gov/pubmed/36172933 http://dx.doi.org/10.1161/JAHA.122.027516 |
_version_ | 1784833006781857792 |
---|---|
author | Yen, Chieh‐Li Fan, Pei‐Chun Lee, Cheng‐Chia Chen, Jia‐Jin Kuo, George Tu, Yi‐Ran Chu, Pao‐Hsien Hsu, Hsiang‐Hao Tian, Ya‐Chung Chang, Chih‐Hsiang |
author_facet | Yen, Chieh‐Li Fan, Pei‐Chun Lee, Cheng‐Chia Chen, Jia‐Jin Kuo, George Tu, Yi‐Ran Chu, Pao‐Hsien Hsu, Hsiang‐Hao Tian, Ya‐Chung Chang, Chih‐Hsiang |
author_sort | Yen, Chieh‐Li |
collection | PubMed |
description | BACKGROUND: The benefit of low‐density lipoprotein cholesterol (LDL‐C) levels in chronic kidney disease populations remains unclear. This study evaluated the cardiovascular and renal outcomes in patients with stage 3 chronic kidney disease with different LDL‐C levels during statin treatment. METHODS AND RESULTS: There were 8500 patients newly diagnosed as having stage 3 chronic kidney disease under statin treatment who were identified from the Chang Gung Research Database and divided into 3 groups according to their first LDL‐C level after the index date: <70 mg/dL, 70 to 100 mg/dL, and >100 mg/dL. Inverse probability of treatment weighting was performed to balance baseline characteristics. Compared with the LDL‐C ≥100 mg/dL group, the 70≤LDL‐C<100 mg/dL group exhibited significantly lower risks of major adverse cardiac and cerebrovascular events (6.8% versus 8.8%; subdistribution hazard ratio [SHR], 0.76 [95% CI, 0.64–0.91]), intracerebral hemorrhage (0.23% versus 0.51%; SHR, 0.44 [95% CI, 0.25–0.77]), and new‐onset end‐stage renal disease requiring chronic dialysis (7.6% versus 9.1%; SHR, 0.82 [95% CI, 0.73–0.91]). By contrast, the LDL‐C <70 mg/dL group exhibited a marginally lower risk of major adverse cardiac and cerebrovascular events (7.3% versus 8.8%; SHR, 0.82 [95% CI, 0.65–1.02]) and a significantly lower risk of new‐onset end‐stage renal disease requiring chronic dialysis (7.1% versus 9.1%; SHR, 0.76 [95% CI, 0.67–0.85]). CONCLUSIONS: Among patients with stage 3 chronic kidney disease, statin users with 70≤LDL‐C<100 mg/dL and with LDL‐C <70 mg/dL had similar beneficial effect in the reduction of risks of major adverse cardiac and cerebrovascular events and new‐onset end‐stage renal disease compared with those with LDL‐C >100 mg/dL. Moreover, the 70≤LDL‐C<100 mg/dL group seemed to have a lowest risk of intracerebral hemorrhage, although the incidence was low. |
format | Online Article Text |
id | pubmed-9673722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96737222022-11-21 Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease Yen, Chieh‐Li Fan, Pei‐Chun Lee, Cheng‐Chia Chen, Jia‐Jin Kuo, George Tu, Yi‐Ran Chu, Pao‐Hsien Hsu, Hsiang‐Hao Tian, Ya‐Chung Chang, Chih‐Hsiang J Am Heart Assoc Original Research BACKGROUND: The benefit of low‐density lipoprotein cholesterol (LDL‐C) levels in chronic kidney disease populations remains unclear. This study evaluated the cardiovascular and renal outcomes in patients with stage 3 chronic kidney disease with different LDL‐C levels during statin treatment. METHODS AND RESULTS: There were 8500 patients newly diagnosed as having stage 3 chronic kidney disease under statin treatment who were identified from the Chang Gung Research Database and divided into 3 groups according to their first LDL‐C level after the index date: <70 mg/dL, 70 to 100 mg/dL, and >100 mg/dL. Inverse probability of treatment weighting was performed to balance baseline characteristics. Compared with the LDL‐C ≥100 mg/dL group, the 70≤LDL‐C<100 mg/dL group exhibited significantly lower risks of major adverse cardiac and cerebrovascular events (6.8% versus 8.8%; subdistribution hazard ratio [SHR], 0.76 [95% CI, 0.64–0.91]), intracerebral hemorrhage (0.23% versus 0.51%; SHR, 0.44 [95% CI, 0.25–0.77]), and new‐onset end‐stage renal disease requiring chronic dialysis (7.6% versus 9.1%; SHR, 0.82 [95% CI, 0.73–0.91]). By contrast, the LDL‐C <70 mg/dL group exhibited a marginally lower risk of major adverse cardiac and cerebrovascular events (7.3% versus 8.8%; SHR, 0.82 [95% CI, 0.65–1.02]) and a significantly lower risk of new‐onset end‐stage renal disease requiring chronic dialysis (7.1% versus 9.1%; SHR, 0.76 [95% CI, 0.67–0.85]). CONCLUSIONS: Among patients with stage 3 chronic kidney disease, statin users with 70≤LDL‐C<100 mg/dL and with LDL‐C <70 mg/dL had similar beneficial effect in the reduction of risks of major adverse cardiac and cerebrovascular events and new‐onset end‐stage renal disease compared with those with LDL‐C >100 mg/dL. Moreover, the 70≤LDL‐C<100 mg/dL group seemed to have a lowest risk of intracerebral hemorrhage, although the incidence was low. John Wiley and Sons Inc. 2022-09-29 /pmc/articles/PMC9673722/ /pubmed/36172933 http://dx.doi.org/10.1161/JAHA.122.027516 Text en © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Yen, Chieh‐Li Fan, Pei‐Chun Lee, Cheng‐Chia Chen, Jia‐Jin Kuo, George Tu, Yi‐Ran Chu, Pao‐Hsien Hsu, Hsiang‐Hao Tian, Ya‐Chung Chang, Chih‐Hsiang Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease |
title | Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
|
title_full | Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
|
title_fullStr | Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
|
title_full_unstemmed | Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
|
title_short | Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
|
title_sort | association of low‐density lipoprotein cholesterol levels during statin treatment with cardiovascular and renal outcomes in patients with moderate chronic kidney disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673722/ https://www.ncbi.nlm.nih.gov/pubmed/36172933 http://dx.doi.org/10.1161/JAHA.122.027516 |
work_keys_str_mv | AT yenchiehli associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease AT fanpeichun associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease AT leechengchia associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease AT chenjiajin associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease AT kuogeorge associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease AT tuyiran associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease AT chupaohsien associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease AT hsuhsianghao associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease AT tianyachung associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease AT changchihhsiang associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease |